Sun Pharmaceuticals today reported a 244.4 per cent jump in net profit at Rs 564.3 crore for the quarter ended June 30, compared to Rs 163.8 crore in the year-ago period.
The spurt in profit was due to a one-time sale of generic cancer drug oxaliplatin in the US, according to industry analysts. Total income rose 77.1 per cent to Rs 1,399.7 crore, compared to Rs 787.6 crore in the comparable period a year ago.
Sun Pharma Chairman and Managing Director Dilip Shanghvi said the business had been positive, with growth coming from all business segments in line with expectations and guidance.
During the quarter, the company’s US subsidiary, Caraco, recorded sales of $130 million (about Rs 605 crore), up by 171 per cent over the year-ago period, aided by one-time sale of generic oxaliplatin (Eloxatin).
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app